Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Helus Pharma reported fiscal 2026 financial results with cash totaling $157.3 million and a net loss of $148.0 million, driven by increased investment in Phase 3 trials. The company highlighted the completion of a $50 million underwritten offering and announced that its Phase 3 APPROACH study for HLP003 in Major Depressive Disorder has surpassed 88% enrollment. Helus Pharma strengthened its leadership team with the appointment of Dr.
Key figures
- Drug Name
- HLP003
- Phase Of Trial
- Phase 3
- Opex fy
- $131.7 million
- Net loss fy
- $148.0 million
- Net loss q4
- $47.0 million
- Cash balance
- $157.3 million
- Hlp003 enrollment
- >88%
- Offering proceeds
- $50 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.